ABSTRACT
Objective To identify risk factors for first episodes of suicidal ideation and suicide attempt in people with functional/dissociative seizures (FDS) or epilepsy.
Methods Retrospective cohort study from the UK’s largest tertiary mental health care provider, with linked national admission data from the Hospital Episode Statistics (HES). Participants were 2383 people with a primary or secondary diagnosis of FDS or epilepsy attending between 01/01/2007 and 18/06/2021. Outcomes were a first report of suicidal ideation and a first hospital admission for suicide attempt (ICD-10 X60-X84). Demographic and clinical risk factors were assessed using multivariable bias-reduced binomial-response generalised linear models.
Results In both groups, ethnic minorities had significantly reduced odds of hospitalisations following a suicide attempt (OR: 0.45 – 0.49). Disorder-specific risk factors were gender, age, and comorbidity profile. In FDS, both genders had similar risk of suicidality; younger age was a risk factor for both outcomes (OR: 0.16 – 1.91) and a diagnosis of Depression or Personality Disorders was associated with higher odds of reporting suicidal ideation (OR: 1.91 and 3.01 respectively). In epilepsy, females had higher odds of being hospitalised following suicide attempt (OR: 1.64). Age had a quadratic association with both outcomes (OR: 0.88 – 1.06). A Substance Abuse Disorder was associated to higher suicidal ideation (OR: 2.67) whilst Developmental Disorders lowered the risk (OR: 0.16 – 0.24).
Conclusions This is the first study systematically reporting risk factors for suicidality in people with FDS. Results for the large epilepsy cohort complement previous studies and will be useful in future meta-analyses.
KEY MESSAGE BOX
What is already known on this topic
People with epilepsy and people with functional/dissociative seizures (FDS) are at elevated risk of suicide
Identification of risk factors for suicidal ideation and suicide attempt in high-risk groups is essential to inform risk prevention strategies
What this study adds
Several factors are associated with suicidality in FDS, including age, ethnicity, comorbid Depression and Personality Disorders.
In epilepsy, suicidality is associated with age, gender, ethnicity, comorbid Substance Misuse Disorder and Developmental Disorders.
How this study might affect research, practice or policy
Whilst disorder-specific factors will be useful to identify groups at higher risk in clinical settings, general risk factors can be target of population-based preventive strategies.
Competing Interest Statement
Irene Faiman, John Hodsoll, Iman Jasani, Paul Shotbolt: none to declare. Allan H. Young: Employed by King s College London; Honorary Consultant SLaM (NHS UK) Deputy Editor, BJPsych Open. Paid lectures and advisory boards for the following companies with drugs used in affective and related disorders: Astrazeneca, Eli Lilly, Lundbeck, Sunovion, Servier, Livanova, Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma, COMPASS, Sage, Novartis. Consultant to Johnson & Johnson. Consultant to Livanova. Received honoraria for attending advisory boards and presenting talks at meetings organised by LivaNova. Principal Investigator in the Restore-Life VNS registry study funded by LivaNova. Principal Investigator on ESKETINTRD3004: An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression. Principal Investigator on The Effects of Psilocybin on Cognitive Function in Healthy Participants. Principal Investigator on The Safety and Efficacy of Psilocybin in Participants with Treatment-Resistant Depression (P-TRD). UK Chief Investigator for Novartis MDD study MIJ821A12201. Grant funding (past and present): NIMH (USA); CIHR (Canada); NARSAD (USA); Stanley Medical Research Institute (USA); MRC (UK); Wellcome Trust (UK); Royal College of Physicians (Edin); BMA (UK); UBC-VGH Foundation (Canada); WEDC (Canada); CCS Depression Research Fund (Canada); MSFHR (Canada); NIHR (UK). Janssen (UK). No shareholdings in pharmaceutical companies.
Funding Statement
This work was supported by the Bergqvist Charitable Trust through the Psychiatry Research Trust as a PhD scholarship to Irene Faiman. This study represents independent research partly funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King s College London.
Professor Young s independent research is funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King s College London.
The funders were not involved in any aspects of this work s planning, execution, article preparation or in the decision to submit the article for publication. The views expressed are those of the authors and not necessarily those of the funding Trusts, the NHS, the NIHR, or the Department of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The CRIS Oversight Committee s review (project number 19-088; 14/11/2019 approval under Oxfordshire C Research Ethics 23/SC/0257) gave ethical approval for secondary analysis of CRIS data
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
DATA AVAILABILITY STATEMENT
Data may be obtained from a third party and are not publicly available. Access to Clinical Record Interactive Search (CRIS) data used for this study is regulated by the CRIS Oversight Committee and the ‘Oxfordshire C’ Research Ethics approval for secondary analysis of CRIS data (23/SC/0257). Data used for this research cannot be shared without prior approval from the CRIS Oversight Committee. Those interested should contact Robert Stewart (robert. stewart{at}kcl.ac.uk), CRIS academic lead.
